Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.
The company is beginning a multi-site Phase II trial designed to establish that its approach can identify patients who will respond to immuno-oncology drugs.
Acepodia's off-the-shelf cell therapy uses an antibody-cell conjugate to target human HER2-expressing solid tumors.
The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.
The company will submit the data as part of a new drug application for pralsetinib for RET fusion-positive non-small cell lung cancer.
The CVS-Tempus partnership aims to streamline the cancer care process for patients from the point of prescribing onwards and connect patients with local trials.
The partners will focus on optimizing technology and conducting clinical utility studies for liquid biopsy and tissue-based genomic applications.
Transgene and NEC are working together to use artificial intelligence to tailor immunotherapy to individual patients.
CStone and Blueprint enrolled the first patient in a trial exploring the combination of the FGFR4 inhibitor fisogatinib and a PD-L1 inhibitor.
Researchers developed a feature mapping algorithm to pair cancer patients with precision oncology trials at Stanford but say increased clinical trial standardization is needed.
Despite the availability of more personalized options, the market dynamics are getting more complex and oncologists need education and tools to keep up with advances.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
A Sun-Yat Sen University Cancer Center-led team found circulating tumor DNA methylation patterns could detect colorectal cancer among asymptomatic individuals.
The randomized, 400-patient trial will compare selpercatinib to chemotherapy for first-line treatment of medullary thyroid cancer.
The drug is approved as a maintenance treatment for platinum-responsive metastatic pancreatic cancer patients with germline BRCA1/2 mutations.
Experimental EGFR inhibitor fell short of desired objective response rate in patients with non-small cell lung cancer.
A Phase I/II clinical trial for OBI-999, a new antibody-drug conjugate, is enrolling patients.
The company plans to make its PRS offering, currently used only in those who test negative for gene mutations, an option for all customers of European ancestry.